期刊文献+

老年急性冠状动脉综合征合并糖尿病患者介入治疗的疗效和预后 被引量:4

Acute-stage and long-term efficacy of PCI in old patients with ACS complicated with diabetes
暂未订购
导出
摘要 目的评价老年急性冠状动脉综合征(ACS)合并糖尿病患者PCI的效果和预后。方法选择年龄>65岁的老年ACS行PCI患者232例,按是否合并糖尿病分为合并组(76例)和非合并组(156例),两组均行药物洗脱支架置入,合并组急诊PCI 17例(22.4%),非合并组急诊PCI 41例(26.3%)。随访6个月~4年,观察两组患者手术成功率、住院期间和远期心脑血管事件发生率。结果合并组患者女性和3支血管病变比例明显高于非合并组(P<0.05,P<0.01)。合并组和非合并组PCI成功率比较差异无统计学意义(97.5%vs 97.6%,P>0.05)。两组术后并发症、住院期间和远期心脑血管事件发生率比较差异无统计学意义(P>0.05)。结论ACS合并糖尿病患者PCI成功率高,PCI安全有效。 Objective To assess the efficacy and prognosis of the treatment of percutaneous coronary intervention(PCI) in the elderly patients with acute coronary syndrome complicated with diabetes mellitus(ACS+DM). Methods Patients(age〉65) with acute coronary syndrome(ACS) underwent PCI. Seventy-six patients were suffering from ACS+DM,and 126 patients were suffering from ACS without DM(NDMACS). They were all treated with drug-eluting stents. Emergen- cy PCI was performed in 17 patients(22.4%) in ACS+DM group and 41 patients(26.3%) in NDMACS group. The incidence of major adverse cardiac events during stay in hospital and the follow up period were observed. Results The proportions of females and patients with triple-ves- sel coronary disease in the ACS+ DM group were significantly higher than those in NDMACS group (P ~ 0.05 ,P ~ 0.01). There was no significant difference of the rate of successful PCI between these two groups (P 〉 0.05). There was no significant difference in complications and incidence of major adverse cardiac and cerebral events during stay in hospital and follow-up period between the two groups also (P 〉 0.05). Conclusions In the ACS+DM patients PCI was highly successful. PCI is safe and effective for the elderly patients with ACS+DM.
出处 《中华老年心脑血管病杂志》 CAS 北大核心 2009年第11期837-839,共3页 Chinese Journal of Geriatric Heart,Brain and Vessel Diseases
关键词 冠心痛 糖尿病 支架 冠状动脉疾病 冠状血管造影术 危险因素 coronary disease diabetes mellitus stents coronary artery disease coronary angiogra-phy risk factors
  • 相关文献

参考文献7

  • 1田声放,万峰,祝庆,屈根学,柏本健,王海欣,马俊,王怀军,梁刚.冠心病合并糖尿病患者冠状动脉旁路移植术长期预后及危险因素的探讨[J].中华心血管病杂志,2002,30(5):272-275. 被引量:9
  • 2S. M. Haffner.Impaired glucose tolerance – is it relevant for cardiovascular disease?[J].Diabetologia.1997(2)
  • 3Ledru F,Ducimetiere P,Battaglia S,et al.New diagnostic criteria for diabetes and coronary artery disease: insights from an angiographic study[].Journal of the American College of Cardiology.2001
  • 4Kip K E,Faxon D P,Detre K M,et al.Coronary angioplasty in diabetic patients: the national heart, lung, and blood institute percutaneous transluminal coronary angioplasty registry[].Circulation.1996
  • 5ADVANCE Collaborative Group.Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes[].New England Journal of Medicine The.2008
  • 6Marenzi G,Lauri G,Assanelli E,et al.Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction[].Journal of the American College of Cardiology.2004
  • 7Hol man RR,Sanjoy KP,Bethel MA,et al.10-Year Follow-up of intensive glucose control in type2diabetes[].The New England Journal of Medicine.2008

二级参考文献1

  • 1S. M. Haffner. Impaired glucose tolerance – is it relevant for cardiovascular disease?[J] 1997,Diabetologia(2):S138~S140

共引文献8

同被引文献24

  • 1霍勇.伴随循证医学走入真实世界——GRACE研究给我们的提示[J].中华医学信息导报,2002,17(11):12-13. 被引量:12
  • 2Fox KA, Goodman SG, Klein W, et al. Global registry of acute coro- nary events[J]. Eur Heart, 2002, 23(15) :1177.
  • 3Granger CB, Goldberg RJ, Dabbous OH, et al. For the global regis- try of acute corormry events investigation. Predictors of hospital-mor- tality in the global registry of acute coronary events [ J ]. Arch Intern Med, 2003, 163(19) :2345.
  • 4Terkelsen CJ, Vach W. Can risk score models help in reducing seri- ous outcome events in patients with stable angina? [ J ]. BMJ, 2005, 331 (7521) :869.
  • 5Sean M, Garrick C, Carolyn H, et al. Diabetes and mortality follow- ing acute coronary syndromes [ J ]. JAMA, 2007, 298 ( 7 ) : 765 - 775.
  • 6Sabia H, Prasad P, Smith HT,et al. Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolemia. J Cardiovasc Pharmacol, 2001,37 (5):502- 511.
  • 7Evans M. Total lipid management and residual risk: beyond statin therapy. Br J Hosp Med (Lond), 2011,72(3 ) : 132-136.
  • 8Lee YH, Lee SH, Jung ES, et al. Visceral adiposity and the severity of coronary artery disease in middle-aged subjects with normal waistcircumference and its relation with lipocalin-2 and MCP-1. Atherosclerosis, 2010,213(2) :592-597.
  • 9Xu DY, Shu J, Huang QY, et al. Evaluation of the lipid lowering ability, anti-inflammatory effects and clinical safety of intensive therapy with Zhibitai, a Chinese traditional medicine. Atherosclerosis, 2010,211 ( 1 ) : 237 -241.
  • 10Izidoro-Toledo TC, Guimaraes DA, Belo VA, et al. Effects of statins on matrix metalloproteinases and their endogenous inhibitors in human endothelial cells. Naunyn Schmiedebergs Arch Pharmacol, 2011,383(6) : 547-554.

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部